Established Medical Therapy for Benign Prostatic Hyperplasia

Urologic Clinics of North America

Volumn 36, Issue 4, 2009, Pages 443-459

  Auffenberg, Gregory B ^a   Helfand, Brian T ^a   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

5 alpha reductase inhibitor; Alpha blocker; Anti cholinergic; Benign prostatic hyperplasia; Phytotherapeutics

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CUCURBITA PEPO EXTRACT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; HYPOXIS ROOPERI EXTRACT; OPUNTIA EXTRACT; PHENOXYBENZAMINE; PICEA EXTRACT; PINUS EXTRACT; PLACEBO; PLANT EXTRACT; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SECALE CEREALE EXTRACT; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT;

CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE MODEL; DIZZINESS; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; GYNECOMASTIA; HEART ARRHYTHMIA; HORMONAL THERAPY; HUMAN; HYPOTENSION; HYPOXIS ROOPERI; IMPOTENCE; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; MEDICINAL PLANT; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; RETROGRADE EJACULATION; REVIEW; RYE; SEXUAL DYSFUNCTION; SPRUCE; SQUASH; SYNCOPE; TACHYCARDIA;

ADRENERGIC ALPHA-ANTAGONISTS; CHOLINERGIC ANTAGONISTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PHYTOTHERAPY; PROSTATIC HYPERPLASIA; PROSTATISM;

EID: 70449698018     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.07.004     Document Type: Review

References (104)

1. Lee C., Kozlowski J.M., and Grayhack J.T. Etiology of benign prostatic hyperplasia. Urol Clin North Am 22 2 (1995) 237-246
2. Lee C., Kozlowski J.M., and Grayhack J.T. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 31 2 (1997) 131-138
3. Reynard J.M. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?. Curr Opin Urol 14 1 (2004) 13-16
4. Di Silverio F., Gentile V., Pastore A.L., et al. Benign prostatic hyperplasia: what about a campaign for prevention?. Urol Int 72 3 (2004) 179-188
5. O'Leary M.P. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 62 3 Suppl 1 (2003) 15-23
6. Gushchin G.L., Jones C.A., and Nyberg L.M. Decline in the surgical treatment of benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. [abstract]. J Urol 157 (1997) 311
7. Wasson J.H., Bubolz T.A., Lu-Yao G.L., et al. Transurethral resection of the prostate among Medicare beneficiaries: 1984 to 1997. For the Patient Outcomes Research Team for Prostatic Diseases. J Urol 164 4 (2000) 1212-1215
8. Baine W.B., Yu W., Summe J.P., et al. Epidemiologic trends in the evaluation and treatment of lower urinary tract symptoms in elderly male Medicare patients from 1991 to 1995. J Urol 160 3 Pt 1 (1998) 816-820
9. Caine M., Raz S., and Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 47 2 (1975) 193-202
10. Furuya S., Kumamoto Y., Yokoyama E., et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 128 4 (1982) 836-839
11. Kobayashi S., Tang R., Shapiro E., et al. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol 150 6 (1993) 2002-2006
12. Lepor H., and Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol 70 Suppl 1 (1992) 2-9
13. Yokoyama E., Furuya S., and Kumamoto Y. [Quantitation of alpha-1 and beta adrenergic receptor densities in the human normal and hypertrophied prostate]. Nippon Hinyokika Gakkai Zasshi 76 3 (1985) 325-337 [in Japanese]
14. Roehrborn C.G., Lukkarinen O., Mark S., et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 96 4 (2005) 572-577
15. Roehrborn C.G., Marks L.S., Fenter T., et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63 4 (2004) 709-715
16. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 22 2 (1995) 375-386
17. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 45 3 (1995) 406-413
18. Price D.T., Schwinn D.A., Lomasney J.W., et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 150 2 Pt 1 (1993) 546-551
19. Malloy B.J., Price D.T., Price R.R., et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol 160 3 Pt 1 (1998) 937-943
20. Smith M.S., Schambra U.B., Wilson K.H., et al. Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 63 2 (1999) 254-261
21. Andersson K.-E., and Wein A.J. Pharmacology of the lower urinary tract-basis for current and future treatments of urinary incontinence. Pharmacol Rev 56 4 (2004) 581-631
22. Hampel C., Dolber P.C., Smith M.P., et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167 3 (2002) 1513-1521
23. Gu B., Reiter J.P., Schwinn D.A., et al. Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction. J Urol 172 2 (2004) 758-762
24. Nomiya M., and Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170 2 Pt 1 (2003) 649-653
25. Das A.K., Leggett R.E., Whitbeck C., et al. Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn 21 2 (2002) 160-166
26. Pinggera G.-M., Schuster A., Pallwein L., et al. Alpha-blockers increase vesical and prostatic blood flow and bladder capacity. [abstract]. Eur Urol 159 Suppl 2 (2003) 628
27. Beduschi M.C., Beduschi R., and Oesterling J.E. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist. Urology 51 6 (1998) 861-872
28. Abrams P., Hollister P., Lawrence J., et al. Bladder outflow obstruction treated with phenoxybenzamine. Preliminary note. Br J Urol 54 5 (1982) 530
29. Caine M., Perlberg S., and Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50 7 (1978) 551-554
30. Caine M., Perlberg S., and Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. 1978 [editorial]. J Urol 167 2 Pt 2 (2002) 1101
31. Caine M., Perlberg S., and Shapiro A. Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases. Urology 17 6 (1981) 542-546
32. Chapple C.R., Wyndaele J.J., Nordling J., et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 29 2 (1996) 155-167
33. Michel M.C., Flannery M.T., and Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 58 4 (2001) 508-516
34. Shibata K., Foglar R., Horie K., et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 48 2 (1995) 250-258
35. Lee M. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm 60 14 (2003) 1426-1439
36. Roehrborn C.G., Oesterling J.E., Auerbach S., et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 47 2 (1996) 159-168
37. Kirby R.S. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 46 2 (1995) 182-186
38. Roehrborn C.G., and Siegel R.L. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 48 3 (1996) 406-415
39. Kirby R.S., Roehrborn C., Boyle P., et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61 1 (2003) 119-126
40. Roehrborn C.G. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 58 6 (2001) 953-959
41. Roehrborn C.G., Van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92 3 (2003) 257-261
42. Abrams P., Schulman C.C., and Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 76 3 (1995) 325-336
43. Dunn C.J., Matheson A., and Faulds D.M. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 19 2 (2002) 135-161
44. Michel M.C., Mehlburger L., Bressel H.U., et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1 6 (1998) 332-335
45. Michel M.C., Mehlburger L., Bressel H.U., et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?. J Urol 160 3 Pt 1 (1998) 784-791
46. van Kerrebroeck P., Jardin A., Laval K.U., et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 37 3 (2000) 306-313
47. Kawabe K., Yoshida M., and Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98 5 (2006) 1019-1024
48. Wilt T.J., Howe W., and MacDonald R. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 89 3 (2002) 214-225
49. Partin A.W. Etiology of benign prostatic hyperplasia (2000), WB Saunders Co, Philadelphia p. 95-100
50. Coffey D.S., and Walsh P.C. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17 3 (1990) 461-475
51. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 327 17 (1992) 1185-1191
52. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 9 (1998) 557-563
53. Evans H.C., and Goa K.L. Dutasteride. Drugs Aging 12 20 (2003) 905-916 [discussion: 17-18]
54. Gisleskog P.O., Hermann D., Hammarlund-Udenaes M., et al. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 64 6 (1998) 636-647
55. Shirakawa T., Okada H., Acharya B., et al. Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate 58 1 (2004) 33-40
56. Thigpen A.E., Davis D.L., Milatovich A., et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 90 3 (1992) 799-809
57. Roehrborn C.G., Boyle P., Nickel J.C., et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 3 (2002) 434-441
58. Physician's Desk Reference. 62 nd edition (2008), Thompson Healthcare, Inc, Montvale (NJ) p. 1375, 2083
59. Lieber M.M., Jacobsen S.J., Roberts R.O., et al. Prostate volume and prostate-specific antigen in the absence of prostate cancer: a review of the relationship and prediction of long-term outcomes. Prostate 49 3 (2001) 208-212
60. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270 7 (1993) 860-864
61. Boyle P., Gould A.L., and Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48 3 (1996) 398-405
62. Guess H.A., Heyse J.F., and Gormley G.J. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 22 1 (1993) 31-37
63. Guess H.A., Heyse J.F., Gormley G.J., et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 20 4 (1993) 627-636
64. Lange P.H. Is the prostate pill finally here?. N Engl J Med 327 17 (1992) 1234-1236
65. Oesterling J.E., Roy J., Agha A., et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 50 1 (1997) 13-18
66. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 3 (2003) 215-224
67. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 18 (2007) 1375-1383
68. Data show Dutasteride reduces prostate cancer diagnosis in men with increased risk, in article number 130, vol. 2009. Available at: www.auanet.org/content/press/press-release/article.cfm.
69. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 335 8 (1996) 533-539
70. Bautista O.M., Kusek J.W., Nyberg L.M., et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 24 2 (2003) 224-243
71. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 25 (2003) 2387-2398
72. Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179 2 (2008) 616-621 [discussion: 21]
73. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 187 1 (2002) 116-126
74. Abrams P., Kaplan S., De Koning Gans H.J., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 3 Pt 1 (2006) 999-1004 [discussion]
75. Blake-James B.T., Rashidian A., Ikeda Y., et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99 1 (2007) 85-96
76. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 19 (2006) 2319-2328
77. Bales G.T., Christiano A.P., Kirsh E.J., et al. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 54 1 (1999) 86-89
78. Lowe F.C. Phytotherapy in the management of benign prostatic hyperplasia. Urology 58 6 Suppl 1 (2001) 71-76 [discussion: 76-7]
79. Dedhia R.C., and McVary K.T. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 179 6 (2008) 2119-2125
80. Dreikorn K., Borkowsi A., Braeckman J., et al. Other medical therapies. In: Denis L., Griffiths K., Khoury S., et al. (Eds). The 4th International Consultation on BPH Plymouth, United Kingdom (1998), Health Publications 633-659
81. Buck A.C. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172 5 Pt 1 (2004) 1792-1799
82. Weisser H., Tunn S., Behnke B., et al. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28 5 (1996) 300-306
83. Hill B., and Kyprianou N. Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate 61 1 (2004) 73-80
84. Rhodes L., Primka R.L., Berman C., et al. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate 22 1 (1993) 43-51
85. Vela-Navarrete R., Escribano-Burgos M., Farre A.L., et al. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 173 2 (2005) 507-510
86. Goepel M., Hecker U., Krege S., et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 38 3 (1999) 208-215
87. Cao N., Haynes J.M., and Ventura S. Saw palmetto is an indirectly acting sympathomimetic in the rat-isolated prostate gland. Prostate 66 2 (2006) 115-123
88. Goepel M., Dinh L., Mitchell A., et al. Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo?. Prostate 46 3 (2001) 226-232
89. Boyle P., Robertson C., Lowe F., et al. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93 6 (2004) 751-756
90. Wilt T.J., Ishani A., Stark G., et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280 18 (1998) 1604-1609
91. Gerber G.S., Kuznetsov D., Johnson B.C., et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 58 6 (2001) 960-964 [discussion: 4-5]
92. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 6 (2006) 557-566
93. Willetts K.E., Clements M.S., Champion S., et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 92 3 (2003) 267-270
94. Complementary and Alternative Medicine for Urological Symptoms (CAMUS). 2009. Available at: www.clinicaltrial.gov.
95. Boulbes D., Soustelle L., Costa P., et al. Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts. BJU Int 98 5 (2006) 1106-1113
96. Choo M.S., Bellamy F., and Constantinou C.E. Functional evaluation of Tadenan on micturition and experimental prostate growth induced with exogenous dihydrotestosterone. Urology 55 2 (2000) 292-298
97. Lawson R.K. Role of growth factors in benign prostatic hyperplasia. Eur Urol 32 Suppl 1 (1997) 22-27
98. Paubert-Braquet M., Cave A., Hocquemiller R., et al. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. J Lipid Mediat Cell Signal 9 3 (1994) 285-290
99. Yoshimura Y., Yamaguchi O., Bellamy F., et al. Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. Urology 61 2 (2003) 474-478
100. Levin R.M., Riffaud J.P., Bellamy F., et al. Effects of tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol 156 6 (1996) 2084-2088
101. Ishani A., MacDonald R., Nelson D., et al. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 109 8 (2000) 654-664
102. Melo E.A., Bertero E.B., Rios L.A., et al. Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz J Urol 28 5 (2002) 418-425
103. Lowe F.C., and Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 48 1 (1996) 12-20
104. Wilt T., Ishani A., MacDonald R., et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev 2 (2000) CD001043